ERBB2 and breast carcinoma: The clinicopathological features of the HER2-positive group were comparable to the TNBC group, with a marginally higher frequency of lymphovascular invasion (79% versus 62%, Chi-squared test, P = 0.02) and of higher nodal stage (pN3 27% versus 15%, Chi-squared test, P = 0.04) in HER2-positive breast cancer patients (Table 1).